Diabetes News and Research

Latest Diabetes News and Research

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

An experimental oral drug has lowered blood sugar levels and inflammation in mice with Type 2 diabetes, suggesting that the medication could someday be added to the arsenal of drugs used by millions of Americans with this disease, according to new research.

16 Mar 2010

Arthritis drug could be useful for treating patients with type 2 diabetes

Clinical studies of a generic drug called salsalate, widely prescribed for arthritis, now provide early promising results that it may be useful for the treatment of patients with type 2 diabetes as well.

16 Mar 2010

NKF: Certain ethnic minorities are at higher risk for developing CKD

Certain ethnic minorities, including African Americans and Hispanics, are at a higher risk than the general population for developing potentially life-threatening chronic kidney disease (CKD), which has been linked to higher rates of diabetes and high blood pressure, according to the National Kidney Foundation.

16 Mar 2010

Unani.ca consumer-minded PEHR now available in Canadian marketplace

The McGill University Health Centre announced today that anyone with an Internet access and a desire to manage his or her health and well-being can now subscribe to Unani.ca. Co-developed with Quebec-owned Medical.MD, Unani.ca is the first consumer-minded personal electronic health record (PEHR) in the Canadian marketplace that combines the expertise of a world-class academic health centre with that of award-winning information-technology developers.

16 Mar 2010

Novo Nordisk awarded funds to support diabetes summer camps nationwide

Novo Nordisk Inc., a world leader in diabetes care, announced that it has awarded funds to support scholarships and capital improvements to diabetes summer camps at fifteen locations nationwide. In support of their dedication to meeting the needs of children with diabetes, the grants will help the camps provide financial assistance programs to campers and improve facilities for the campers' use.

From Novo Nordisk 16 Mar 2010

Global Nutrition Transition Conference: Physicians and nutrition scientists to discuss solutions for preventing obesity

Physicians and nutrition scientists from around the world gathered today in Orlando for the opening of the Global Nutrition Transition Conference in order to discuss emerging trends and grass roots solutions to the global obesity epidemic employing balanced nutrition and teaching healthy active lifestyles.

16 Mar 2010

Roche Diagnostics named sole source supplier for Premier's blood glucose monitoring devices

Roche Diagnostics announced today that it has been awarded contracts for blood glucose monitoring and clinical chemistry/immunoassay lab analyzers from Premier Purchasing Partners, L.P., Inc., the group purchasing unit of Premier, Inc. Roche was also named the sole source supplier for blood glucose in Premier's exclusive ASCEND supply chain performance program.

From Roche Sequencing and Life Science 16 Mar 2010

Publix Pharmacies launches first phase of new diabetes management system

Today Publix Pharmacies launched the first phase of a new diabetes management system. The program is a multi-faceted program established to assist customers and associates living with diabetes in managing their medication, compliance, monitoring, education, nutrition and exercise.

16 Mar 2010

Boston Scientific announces results from HORIZONS AMI trial assessing Express bare-metal stent

Boston Scientific Corporation today announced results from an analysis of one-year subset data from the HORIZONS AMI trial assessing the impact of diabetes on clinical and angiographic outcomes in heart attack patients treated with the TAXUS® Express2™ Paclitaxel-Eluting Stent System or the Express® bare-metal stent.

16 Mar 2010

Metabolic drugs top the list of prescription drug expenses for elderly Medicare beneficiaries

Purchases of cholesterol and diabetes prescription drugs by elderly Medicare beneficiaries reached nearly $19 billion in 2007 - about one-fourth of the approximately $82 billion spent for medications for the elderly, according to the latest AHRQ News and Numbers.

16 Mar 2010

CYPHER Sirolimus-eluting Coronary Stent provides better outcome compared to Medtronic’s Endeavor Stent

Investigators reported the long-term follow-up of the largest randomized comparison between the CYPHER® Sirolimus-eluting Coronary Stent and Medtronic’s Endeavor® Stent highlighting significant and sustained clinical differences. These important findings were presented at the American College of Cardiology annual meeting, (ACC 2010) in Atlanta and published on-line in the prestigious journal The Lancet.

16 Mar 2010

Home Diagnostics merges with Nippon Product Acquisition

Nipro Corporation today announced the successful completion of a short-form merger of Home Diagnostics, Inc. with Nipro’s wholly-owned subsidiary, Nippon Product Acquisition Corporation.

16 Mar 2010

TCAD therapy superior to double combinations and monotherapy against influenza viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic and avian influenza viruses. Results of these studies were presented Sunday evening in an oral session at the XII International Symposium on Respiratory Viral Infections being held in Taipei.

15 Mar 2010

High ABI may indicate risk for future heart attacks

The prevalence of abnormal ankle-brachial index (ABI) test results among individuals tested for peripheral arterial disease (PAD)—and who are not considered at high risk of a coronary heart event by Framingham-based risk factors—is high and provides another way to identify those who may be at risk for future heart attacks, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

15 Mar 2010

MannKind receives FDA Complete Response letter for AFREZZA NDA

MannKind Corporation today announced that it has received a Complete Response letter from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA™ (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes mellitus for the control of hyperglycemia.

15 Mar 2010

Ranbaxy resolves generic Actos patent litigation

Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.

15 Mar 2010

MBGH conduct national survey to improve employer-based health improvement and management programs

To better understand and improve the effectiveness of employer-based health improvement and management programs, the Midwest Business Group on Health, conducted a national survey of physician views on employers' health management programs.

15 Mar 2010

Scientists develop nitric oxide-releasing cloth to make therapeutic socks for diabetes patients

Scientists in Texas are reporting development of a first-of-its-kind cloth that releases nitric oxide gas - an advance toward making therapeutic socks for people with diabetes and a wrap to help preserve organs harvested for transplantation. The study is in ACS' Chemistry of Materials, a bi-weekly journal.

15 Mar 2010

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

15 Mar 2010

Rhythm Pharmaceuticals completes $21M Series A equity financing

Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that it has completed the first close on its Series A equity financing of $21 million. The financing was led by MPM Capital and New Enterprise Associates. The funds will be used to develop products licensed from Ipsen.

15 Mar 2010

Diabetes News and Research

Latest Diabetes News and Research

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

Arthritis drug could be useful for treating patients with type 2 diabetes

NKF: Certain ethnic minorities are at higher risk for developing CKD

Unani.ca consumer-minded PEHR now available in Canadian marketplace

Novo Nordisk awarded funds to support diabetes summer camps nationwide

Global Nutrition Transition Conference: Physicians and nutrition scientists to discuss solutions for preventing obesity

Roche Diagnostics named sole source supplier for Premier's blood glucose monitoring devices

Publix Pharmacies launches first phase of new diabetes management system

Boston Scientific announces results from HORIZONS AMI trial assessing Express bare-metal stent

Metabolic drugs top the list of prescription drug expenses for elderly Medicare beneficiaries

CYPHER Sirolimus-eluting Coronary Stent provides better outcome compared to Medtronic’s Endeavor Stent

Home Diagnostics merges with Nippon Product Acquisition

TCAD therapy superior to double combinations and monotherapy against influenza viruses

High ABI may indicate risk for future heart attacks

MannKind receives FDA Complete Response letter for AFREZZA NDA

Ranbaxy resolves generic Actos patent litigation

MBGH conduct national survey to improve employer-based health improvement and management programs

Scientists develop nitric oxide-releasing cloth to make therapeutic socks for diabetes patients

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Rhythm Pharmaceuticals completes $21M Series A equity financing

Genomics - Industry Focus eBook (2nd edition) eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Diabetes News and Research

Latest Diabetes News and Research

Genomics - Industry Focus eBook (2nd edition) eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in